Trial Profile
Phase 1 Study of Antigen-specific Cytotoxic T Lymphocytes Induced by Dendritic Cells Infected by Recombinant Adeno-associated Virus With MUC1 Gene(MUC1-gene-DC-CTL) or Directly Pulsed by MUC1 Peptide(MUC1-peptide-DC-CTL) in Gastric Cancer.
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs MUC1 gene DC-CTL (Primary) ; MUC1 peptide DC-CTL (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- Sponsors Beijing Doing Biomedical
- 01 Sep 2017 Planned End Date changed from 1 Aug 2019 to 1 Apr 2020.
- 01 Sep 2017 Planned primary completion date changed from 1 Mar 2019 to 1 Apr 2019.
- 01 Sep 2017 Planned initiation date changed from 1 Mar 2017 to 1 Oct 2017.